COMMON

The Pershing Square Funds Have Extended Their Tender Offer and Increased the Price Range for up to 6,340,000 Common Shares of The Howard Hughes Corporation

Retrieved on: 
Friday, November 11, 2022
Banking, Professional Services, Finance, Midnight, Indian stock exchange, Purchasing, Company, COMMON, Howard Hughes Corporation, Computershare, Letter, PS, View, Pershing Square Capital Management, SEC, HHC, Forward-looking statement, Expiration date, Jefferies, Jefferies Group, Tender, Offer, NYSE, Pershing Square, Expiration, Security (finance), Auction, Financial adviser, Letter of transmittal

The Purchasers have stated that the newly increased price range represents the Purchasers best and final offer.

Key Points: 
  • The Purchasers have stated that the newly increased price range represents the Purchasers best and final offer.
  • The $70.00 high-end of the price range represents a 28% premium above the closing price of the Common Shares on October 13, 2022, the last trading day prior to the announcement of the Offer.
  • Any extension of the Offer will be announced publicly on the first business day after the Expiration Date.
  • About Pershing Square Capital Management, L.P.
    Pershing Square Capital Management, L.P., based in New York City, is a SEC-registered investment advisor to investment funds.

Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Grubhub Inc. Securities Litigation

Retrieved on: 
Friday, November 11, 2022
Class Action Lawsuit, Professional Services, Legal, Judgement, Lawsuit, Federal Rules of Civil Procedure, COMMON, CLASS, Allocation, Private Securities Litigation Reform Act, Coupon settlement, Hearing, District court, Settlement, Eastern Division, Notice, Class, Class Action, Leading Counsel, Defendant, Court, AND, ALL, Grubhub, Person, Post office box, Clerk, Prince William County, Virginia Clerk of Circuit Court, Generic drug

ALL PERSONS WHO PURCHASED OR ACQUIRED GRUBHUB, INC. (GRUBHUB) COMMON STOCK BETWEEN APRIL 25, 2019 AND OCTOBER 28, 2019, INCLUSIVE

Key Points: 
  • ALL PERSONS WHO PURCHASED OR ACQUIRED GRUBHUB, INC. (GRUBHUB) COMMON STOCK BETWEEN APRIL 25, 2019 AND OCTOBER 28, 2019, INCLUSIVE
    THIS NOTICE WAS AUTHORIZED BY THE COURT.
  • YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.
  • If the Settlement is approved it will resolve all claims in the Litigation.
  • If you purchased or acquired Grubhub common stock during the period between April 25, 2019 and October 28, 2019, inclusive, your rights may be affected by the settlement of this Litigation.

F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research

Retrieved on: 
Monday, November 7, 2022
Patient, Private Securities Litigation Reform Act, Universal asynchronous receiver-transmitter, Population, Securities Exchange Act of 1934, University, Research, Seven Seas, CNS, TIME, Annual report, Clinical Cancer Research, Technology, SEC, Company, Infrared spectroscopy correlation table, American Association for Cancer Research, GLOBE, Sino Biopharmaceutical Limited, Schedule, MD Anderson Cancer Center, Forward-looking statement, PSLRA, DCR, Drug development, Cancer, Drug discovery, Maintenance, Nasdaq, Letter, Terminology, Anaplastic thyroid cancer, Personal Information Agent, PD-L1, Immunotherapy, American Association, Therapy, Time, CD137, Patent, COMMON, Safety, Downregulation and upregulation, IO, Pharmacology, NASDAQ, Risk, Association, Communication, Pharmaceutical industry, Vaccine

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company pioneering bispecific antibodies for immunotherapy so more people with cancer can live longer and improved lives, today announced the publication of safety and efficacy results from Phase 1 trial of FS118 in patients with advanced cancer and PD-L1 resistance in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Key Points: 
  • Phase 1 data published in Clinical Cancer Research demonstrate that FS118 has the potential to overcome cancer immune resistance given the prolonged pharmacodynamic activity, said Louis Kayitalire, Chief Medical Officer of F-star.
  • We look forward to generating additional data and leveraging our bispecific approach to provide therapies for patients with advanced cancer.
  • Weekly administration was well tolerated, with no dose-limiting toxicities (DLTs), and no serious adverse events (SEAs) relating to FS118.
  • In the Phase 1 clinical trial, FS118 was well tolerated with no treatment-related serious adverse events and no dose-limiting toxicity, up to 20mg/kg.

Applied Genetic Technologies Corporation Reminds Shareholders to Tender Their Shares by November 28, 2022

Retrieved on: 
Thursday, November 3, 2022
Neurotology, Central nervous system, Company, ACHM, Therapy, Applied Genetic Technologies Corporation, GLOBE, Letter, COMMON, Bankruptcy, Schedule, Nasdaq, Optogenetics, CNS, TIME, Failure, Central nervous system disease, Retina, Forward-looking statement, Ophthalmology, Acquisition, Technology, SEC, Achievement, Personal Information Agent, Patient, AAV, Communication, Management, Security (finance), Holding company

I am writing today urging you to tender your shares of AGTC common stock in the tender offer.

Key Points: 
  • I am writing today urging you to tender your shares of AGTC common stock in the tender offer.
  • Our board of directors unanimously voted in favor of this acquisition and unanimously recommends that all AGTC stockholders tender their shares.
  • President and Chief Executive Officer, Applied Genetic Technologies Corporation
    AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.
  • Applied Genetic Technologies Corporation Contacts:

Summary Notice to Current Merit Medical Systems, Inc. Stockholders of Derivative Action and Settlement Hearing

Retrieved on: 
Wednesday, November 2, 2022
Failure, Judgement, Hearing, Agreement, District court, Action, Prejudice, Prince William County, Virginia Clerk of Circuit Court, Documentation, John Baker White (clerk of court), LLC, Intention, COMMON, Ownership, District, Court, Suite, Complaint, Notice, The Honourable, Clerk, Exhibit, Party, OF, ALL, Life insurance, Tobacco, Lease, Merit, Settlement

2:21-cv-00346-DBP (the Action), have reached a settlement (the Settlement) to resolve the issues raised in the Action.

Key Points: 
  • 2:21-cv-00346-DBP (the Action), have reached a settlement (the Settlement) to resolve the issues raised in the Action.
  • The Settlement Hearing may be continued by the Court at the Settlement Hearing, or at any adjourned session thereof without further notice to Current Merit Stockholders.
  • A detailed Notice to Current Merit Stockholders (the Notice) describing in greater detail the Action, the proposed Settlement, and the rights of Current Merit Stockholders with regard to the Settlement is available on Merits website at https://www.merit.com/wp-content/uploads/2022/11/Notice-To-MeritMedicalS... .
  • If you are a Current Merit Stockholder, your rights to pursue certain derivative claims on behalf of Merit may be affected by the Settlement.

Syncona to Acquire Applied Genetic Technologies Corporation

Retrieved on: 
Monday, October 24, 2022
Therapy, IRDS, ACHM, CVR, Failure, CVR Partners, Retina, Optogenetics, Achievement, Person, LON, TIME, Money transmitter, Schedule TO, GLOBE, Central nervous system, Risk, Review, Hand, EACH, Security (finance), Technology, Goal, AAV, Cyprus Securities and Exchange Commission, Applied Genetic Technologies Corporation, CNS, Schedule, Central nervous system disease, SEC, Life, COMMON, Patient, Letter of transmittal, Neurotology, Nasdaq, Partnership, Exercise, P.C, Letter, Cryptocurrency, Pharmaceutical industry, Syncona

We share AGTCs passion in developing life changing treatments for patients with diseases with no currently approved therapies, said Chris Hollowood, Chief Investment Officer of Syncona Investment Management Limited.

Key Points: 
  • We share AGTCs passion in developing life changing treatments for patients with diseases with no currently approved therapies, said Chris Hollowood, Chief Investment Officer of Syncona Investment Management Limited.
  • Syncona has significant expertise in AAV gene therapy, and in particular, a strong track record of building retinal gene therapy businesses.
  • Under the terms of the definitive agreement, an indirect subsidiary of Syncona Limited will initiate a tender offer to acquire all outstanding shares of AGTC common stock.
  • Applied Genetic Technologies Corporation Contacts:

SCHOLASTIC CORPORATION ANNOUNCES CASH TENDER OFFER TO PURCHASE UP TO $75 MILLION OF ITS COMMON STOCK

Retrieved on: 
Tuesday, October 25, 2022
News, Bangladesh Securities and Exchange Commission, Personal Information Agent, SEC, SELL, COMMON, Education, LLC, THE, NASDAQ, Scholastic, AND, Tender, Security (finance), Multimedia, Curriculum, Dutch auction, Company, Computershare, Learning, Nasdaq, BofA Securities, Scholastic Corporation, Literacy, Wells Fargo, View, TO, Letter of transmittal, Letter, SPECIAL, Cryptocurrency

Thetenderoffer willexpireonTuesday,November 22,2022at12:00Midnight, attheendoftheday,NewYork City time, unless the tender offer is extended or terminated by the Company.

Key Points: 
  • Thetenderoffer willexpireonTuesday,November 22,2022at12:00Midnight, attheendoftheday,NewYork City time, unless the tender offer is extended or terminated by the Company.
  • If shareholders properly tender shares greater than $75 million in value at the price determined, Scholastic will purchase shares of common stock tendered by those shareholders on a pro rata basis, subject to the "odd lot" and conditional tender offer provisions described in the offer to purchase.
  • SCHOLASTIC'S DIRECTORS HAVE INFORMED SCHOLASTIC THAT THEY DO NOT INTEND TO TENDER COMMON SHARES IN THE OFFER.
  • THIS PRESS RELEASE IS FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO PURCHASE OR THE SOLICITATION OF AN OFFER TO SELL SHARES OF SCHOLASTIC COMMON STOCK.

Pershing Square Capital Management, L.P. Announces that Pershing Square, L.P., Pershing Square International, Ltd., and Pershing Square Holdings, Ltd. Commence Tender Offer for up to 6,340,000 Common Shares of The Howard Hughes Corporation

Retrieved on: 
Friday, October 14, 2022
Professional Services, Finance, Midnight, U.S. Securities and Exchange Commission, Expiration date, PS, SEC, Howard Hughes Corporation, COMMON, LLC, NYSE, Jefferies Group, Purchasing, Indian stock exchange, Pershing Square, HHC, Security (finance), Company, Computershare, Expiration, PSH, Forward-looking statement, Pershing Square Capital Management, Letter, Financial adviser, Letter of transmittal

The Purchasers are making this Offer because they believe the Companys current stock price is below the Companys long-term intrinsic value per share.

Key Points: 
  • The Purchasers are making this Offer because they believe the Companys current stock price is below the Companys long-term intrinsic value per share.
  • Any extension of the Offer will be announced publicly on the first business day after the Expiration Date.
  • Holders interested in tendering their Common Shares must do so in accordance with the procedures set forth in the Offer to Purchase.
  • About Pershing Square Capital Management, L.P.
    Pershing Square Capital Management, L.P. (Pershing Square), based in New York City, is a SEC-registered investment advisor to investment funds.

Nikola Completes Exchange Offer to Acquire Romeo Power Common Stock

Retrieved on: 
Thursday, October 13, 2022
U.S. Securities and Exchange Commission, Communication, New, Risk, Investor relations, SEC, Registration statement, Transport, COMMON, NYSE, Register, Tender, Contract, Corporation, Multimedia, Acquisition, 8-K, Eastern Time Zone, Form, Money transmitter, ARE, Nikola Corporation, Schedule, Forward-looking statement, Letter, California County Routes in zone S, Solution, Security (finance), Exchange

PHOENIX, Oct. 13, 2022 /PRNewswire/ -- Nikola Corporation (Nasdaq: NKLA) ("Nikola"), a provider of zero-emissions transportation and energy infrastructure solutions, todayannounced the successful completion of its exchange offer (the "Offer") to purchase all outstanding shares of common stock of Romeo Power, Inc. (NYSE: RMO).

Key Points: 
  • PHOENIX, Oct. 13, 2022 /PRNewswire/ -- Nikola Corporation (Nasdaq: NKLA) ("Nikola"), a provider of zero-emissions transportation and energy infrastructure solutions, todayannounced the successful completion of its exchange offer (the "Offer") to purchase all outstanding shares of common stock of Romeo Power, Inc. (NYSE: RMO).
  • As of the expiration of the Offer, a total of approximately 93.16 million shares of Romeo common stock had been validly tendered and received, and not validly withdrawn, pursuant to the Offer, representing approximately 50.1% of outstanding shares of Romeo common stock immediately after consummation of the Offer.
  • Nikola intends to proceed with the acquisition of Romeo in which a newly formed subsidiary of Nikola will be merged into Romeo, and any remaining shares of Romeo common stock that were not tendered in the exchange offer will be canceled and converted into the right to receive the same consideration as provided for in the exchange offer.
  • Once the transaction is completed, Romeo will become a wholly owned subsidiary of Nikola and Romeo common stock will no longer be listed or traded on the New York Stock Exchange.

Nikola Reminds Romeo Power Stockholders to Tender Shares in Exchange Offer Ahead of October 12 Deadline

Retrieved on: 
Tuesday, October 11, 2022
Midnight, U.S. Securities and Exchange Commission, Communication, Risk, SEC, Registration statement, Investor relations, Transport, COMMON, NYSE, Register, Tender, Contract, Corporation, Multimedia, Lists of action films, 8-K, Eastern Time Zone, Form, Money transmitter, RMO, TD Ameritrade, ARE, Nikola Corporation, Schedule, Forward-looking statement, Letter, California County Routes in zone S, E-Trade, Solution, Security (finance), Holding company, Financial services, PHOENIX, Exchange

As a result, Romeo stockholders' investment may be subject to substantial risks that are described in the Exchange Offer Materials.

Key Points: 
  • As a result, Romeo stockholders' investment may be subject to substantial risks that are described in the Exchange Offer Materials.
  • Romeo stockholders should act as soon as possible to ensure they meet specific broker processing requirements and can validly tender their shares before the deadline.
  • Romeo stockholders who hold shares of Romeo common stock through a broker, dealer, commercial bank, trust company or other nominee should instruct such broker or other nominee to tender their shares.
  • When you reach an advisor, indicate you are calling regarding the exchange offer by Nikola Corporation to purchase all outstanding shares of Romeo Power, Inc.'s common stock.